EP1045912A1 - Polycetides et leur synthese - Google Patents

Polycetides et leur synthese

Info

Publication number
EP1045912A1
EP1045912A1 EP99901036A EP99901036A EP1045912A1 EP 1045912 A1 EP1045912 A1 EP 1045912A1 EP 99901036 A EP99901036 A EP 99901036A EP 99901036 A EP99901036 A EP 99901036A EP 1045912 A1 EP1045912 A1 EP 1045912A1
Authority
EP
European Patent Office
Prior art keywords
pks
gene
module
polyketide
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99901036A
Other languages
German (de)
English (en)
Inventor
Peter Francis Leadlay
James Staunton
Barrie Wilkinson
Christine Janet Rowe
Ines Ute Bohm
Antony David Buss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800675.2A external-priority patent/GB9800675D0/en
Priority claimed from GBGB9800879.0A external-priority patent/GB9800879D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1045912A1 publication Critical patent/EP1045912A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin

Definitions

  • the present invention relates to processes for preparing novel polyketides, particularly 16-membered ring macrolides, by recombinant synthesis and to the novel polyketides so produced.
  • Polyketide biosynthetic genes or portions of them which may be derived from different polyketide biosynthetic gene clusters are manipulated to allow the production of specific novel polyketides, such as 16-membered ring macrolides, of predicted structure.
  • the invention is particularly concerned with the incorporation of additional genes in order to prepare macrolides of larger size than the natural product, for example 16- membered ring instead of 14-membered ring macrolides.
  • Polyketides are a large and structurally diverse class of natural products that includes many compounds possessing antibiotic or other pharmacological properties, such as erythromycin, tetracyclines, rapamycin, avermectin and
  • polyketides are abundantly produced by Streptomyces and related actinomycete bacteria. They are synthesised by the repeated stepwise condensation of acylthioesters in a manner analogous to that of fatty acid biosynthesis. The greater structural diversity found among natural polyketides arises from the selection of (usually) acetate or propionate as "starter" or
  • “extender” units from the differing degree of processing of the ⁇ -keto group observed after each condensation.
  • processing steps include reduction to ⁇ -hydroxyacyl-, reduction followed by dehydration to 2-enoyl-, and complete reduction to the saturated acylthioester. The stereochemical outcome of these processing steps is also specified for each cycle of chain extension.
  • PKS polyketide synthase
  • natural module refers to the set of contiguous domains, from a ⁇ -ketoacyl-ACP synthase ("KS") gene to the next acyl carrier protein (“ACP”) gene, which accomplishes one cycle of polyketide chain extension.
  • KS ⁇ -ketoacyl-ACP synthase
  • ACP acyl carrier protein
  • combinatorial module is used to refer to any group of contiguous domains (and domain parts), extending from a first point in a first natural module, to a second equivalent point in a second natural module. The first and second points will generally be in core domains which are present in all modules, ie both at equivalent points of respective KS, AT (acyl transferase) or ACP domains.
  • the length of polyketide formed has been altered, in the case of erythromycin biosynthesis, by specific relocation using genetic engineering of the enzymatic domain of the erythromycin-producing PKS that contains the chain releasing thioesterase/cyclase activity (Cortes, J et al. Science (1995) 268:1487-1489; Kao, C. M. et al. J. Am. Chem. Soc. (1995) 117:9105-9106).
  • DNA sequence is deposited in the EMBL/Genbank Database under the accession number X86780.
  • Type II PKSs The second class of PKS, named Type II PKSs, is represented by the synthases for aromatic compounds.
  • Type II PKSs contain only a single set of enzymatic activities for chain extension and these are re-used as appropriate in successive cycles (Bibb, M. J. et al. EMBO J. (1989) 8:2727-2736; Sherman, D.H. et al. EMBO J. (1989) 8:2717-2725; Fernandez-Moreno, M.A. et al. J. Biol. Chem. (1992) 267:19278-19290).
  • the "extender" units for the Type II PKSs are usually acetate units, and the presence of specific cyclases dictates the preferred pathway for cyciisation of the completed chain into an aromatic product (Hutchinson, C. R. and Fujii, I. Annu. Rev. Microbiol. (1995) 49:201-238).
  • Hybrid polyketides have been obtained by the introduction of cloned Type II PKS gene- containing DNA into another strain containing a different Type II PKS gene cluster, for example by introduction of DNA derived from the gene cluster for actinorhodin, a blue-pigmented polyketide from Streptomyces coelicolor, into an anthraquinone polyketide-producing strain of Streptomyces galileus (Bartel, P. L. et al. J. Bacteriol. (1990) 172:4816-4826).
  • International Patent Application Number WO 95/08548 describes the replacement of actinorhodin PKS genes by heterologous DNA from other Type II PKS clusters, to obtain hybrid polyketides.
  • the same International Patent Application WO 95/08548 describes the construction of a strain of Streptomyces coelicolor which substantially lacks the native gene cluster for actinorhodin, and the use in that strain of a plasmid vector pRM5 derived from the low-copy number plasmid vector SCP2 * isolated from Streptomyces coelicolor (Bibb, M. J. and Hopwood, D. A. J. Gen. Microbiol.
  • heterologous PKS-containing DNA may be expressed under the control of the divergent act l/act III promoter region of the actinorhodin gene cluster (Fernandez-Moreno, M. A. et al. J.Biol. Chem. (1992) 267:19278-19290).
  • the plasmid pRM5 also contains DNA from the actinorhodin biosynthetic gene cluster encoding the gene for a specific activator protein, Act ll-orf4.
  • the Act II- orf4 protein is required for transcription of the genes placed under the control of the act l/act III bidirectional promoter and activates expression during the transition from growth to stationary phase in the vegetative mycelium (Hallam, S.
  • Type II PKS clusters in Streptomyces are known to be activated by pathway-specific activator genes (Narva, K. E. and Feitelson, J. S. J. Bacteriol. (1990) 172:326-333; Stutzman-Engwall, K. J. et al J. Bacteriol (1992) 174:144-154;
  • the Dnrl gene product complements a mutation in the actll-orf4 gene of S. coelicolor, implying that Dnrl and Actll-orf4 proteins act on similar targets.
  • a gene (srmR) has been described (EP 0 524 832 A2) that is located near the Type I PKS gene cluster for the macrolide polyketide spiramycin. This gene specifically activates the production of the macrolide polyketide spiramycin, but no other examples have been found of such a gene.
  • no homologues of the Actll-orf4/Dnrl/RedD family of activators have been described that act on Type I PKS genes.
  • PKS gene assembly (particularly of type I) encodes a loading module which is followed by at least one extension module.
  • Fig 2a shows the organisation of the DEBS genes.
  • the first open reading frame encodes the first multi-enzyme or cassette (DEBS 1) which consists of three modules; the loading module (ery- load) and two extension modules (Modules 1 and 2).
  • the loading module comprises an acyl transferase and an acyl carrier protein. This may be contrasted with Fig. 1 of WO93/13663 (referred to above).
  • PCT/GB97/01819 describes in general terms the production of a hybrid PKS gene assembly comprising a loading module and at least one extension module. However it contains no specific disclosure of the preparation of a PKS gene assembly to which extra modules, over the number which would be present in the natural PKS assembly, have been added.
  • the present invention concerns the production of an extended PKS gene assembly comprising a loading module and a plurality of extension modules by inserting a second nucleic acid portion, encoding at least one extension module, into a first nucleic acid portion encoding the loading module and at least one, and preferably a plurality, of extension modules.
  • the nucleic acids are DNA.
  • the extended PKS gene encodes a loading module and from 2 to 7, extension modules.
  • the first portion encodes a loading module and 1 to 6 extension modules and a chain terminating enzyme (generally a thioesterase) and the second portion encodes an extension module.
  • the PKS gene encodes a Type I PKS.
  • PKSs for this purpose are the components of PKSs for the biosynthesis of erythromycin, rapamycin, avermectin, tetronasin, oleandomycin, spiromycin, tylomycin, FK506, midecamycin and rifamycin, for all of which the gene and modular organisation is known at least in part.
  • the extension module or modules inserted into the first nucleic acid portion may be homologous or heterologous. They may be natural sequences derived from the same or from a different source eg the first portion may encode modules of erythromycin PKS and the second portion may encode an extension module of a different PKS such as avermectin. Alternatively the second portion may encode a modified extension module which may be an altered version of a natural module from the same or a different source than the first portion.
  • the second portion may be entirely synthetic or may be an engineered, eg by splicing, module comprising DNA derived from one or more different sources.
  • the first portion may encode a hybrid PKS produced, for example, as described in PCT/GB97/01819. It may even have been produced by prior insertions of extension modules.
  • this aspect of the invention encompasses stepwise addition of a plurality of nucleic acid sequences, wherein each sequence encodes at least one extension module, into an initial nucleic acid portion encoding a loading module and at least one extension module.
  • the loading module encoded in the first portion shows a relaxed specificity, for example the loading module of the avermectin fawj-producing PKS of streptomyces avermitilis; or those loading modules possessing an unusual specificity, for example the loading modules of the rapamycin, FK506- and ascomycin-producing PKSs, all of which naturally accept a shikimate-derived starter unit.
  • the second portion of nucleic acid is inserted between the nucleic acid which encodes the first and second extension modules in the first portion.
  • the second portion of nucleic acid may be inserted between the nucleic acid which encodes the final extension module and that encoding the chain terminating enzyme in the first portion.
  • the end of the gene assembly may also be altered.
  • the normal chain terminating enzyme of a PKS usually thioesterase
  • an enzyme leading to a different type of product may be replaced by use may be made of the enzyme from the rapamycin system that connects the polyketide chain to an aminoacid or, possibly, an aminoacid chain.
  • the latter can be used to synthesise polypeptide/polyketide combinations, eg for producing /?-lactam derivatives.
  • This aspect of the invention is largely concerned with treating PKS gene modules as building blocks and inserting additional blocks into existing assemblies. It might be assumed that the correct places for making and breaking the intermodular connections would be in the linking regions between modules, where previously reported experiments using limited proteolysis have shown those linkers to be on the surface of the protein (Aparicio, J. F. et al. (1994) J. Biol. Chem. 269:8524-8528; Staunton J. et al. (1996) Nature Structure Biol 3:188-192). However it has been found that it may sometimes be preferable to make cuts and joins actually within domains (i.e. the enzyme-coding portions), close to the edges thereof. The DNA is highly conserved here between all modular PKSs and this may aid in the construction of new extended PKS assemblies that can be transcribed.
  • the invention further provides such extended PKS assemblies, vectors containing such gene assemblies, and transformant organisms that can express them.
  • Transformant organisms may harbour recombinant plasmids, or the plasmids may integrate.
  • a plasmid with an int sequence will integrate into a specific attachment site (att) of a host's chromosome.
  • Transformant organisms may be capable of modifying the initial products, eg by carrying out all or some of the biosynthetic modifications normal in the production of erythromycins (as shown in Fig 2b) and other polyketides. Use may be made of mutant organisms such that some of the normal pathways are blocked, eg to produce products without one or more 'natural' hydroxy-groups or sugar groups.
  • the invention further provides novel polyketides as producible, directly or indirectly, by transformant organisms. (This includes polyketides which have undergone enzymic modification).
  • the invention provides novel polyketides obtainable by means of the previous aspects.
  • These include 16-membered ring macrolides which are extended homologues of polyketides, such as erythromycin (and analogues and other derivatives thereof), which naturally exist as 14-membered rings.
  • Novel derivatives of known 16-membered macrolides such as tylosin and rokitamycin (or the leucomycin A5 precursor of rokitamycin) analogues, may also be produced by adding an extension module to PKS assemblies which would naturally produce 14-membered macrolides. These may differ from the corresponding 'natural' compound:
  • analogues of 16-membered macrolides such as tylosin or rokitamycin (particularly the leucomycin A5 precursor of rokitamycin) having the differences from the natural product identified in two or more of items (a) to (c) above.
  • polyketides of which such longer homologues may be prepared include rapamycin, avermectin, tetronasin, oleandomycin, monensin, amphotericin and rifamycin.
  • Ketide/non-ketide fusions may be prepared, as may polyketides (or fusions) cyclised by formation of lactones, hemiketals, ketals, lactams or lactols.
  • Derivatives of any of the aforementioned polyketides which have undergone further processing by non-PKS enzymes eg one or more of hydroxylation, epoxidation, glycosylation and methylation may also be prepared.
  • the present invention provides a method of obtaining novel complex polyketides; and novel methods of producing both known and novel polyketides.
  • the invention provides novel 16-membered macrolides, for example the compounds of formulae (I) and (II), and a new way of producing both those novel compounds and known compounds such as rokitamycin (or leucomycin A5) and tylosin.
  • Other 16-membered macrolides which may be prepared by the method of the present invention include josamycin, spiramycin, miokamycin, leucomycin and midecamycin.
  • the preferred method for making such 16-membered macrolides is to insert DNA encoding an additional extension module into a PKS gene assembly which would normally be expected, when expressed, to produce a 14-membered macrolide.
  • PKS assembly produced according to the present invention would tend to cyclise the polyketide chain so as to produce a macrolide having the natural number of ring members.
  • an additional extension module is inserted into an erythromycin assembly
  • the erythromycin thioesterase would continue to attack the group added by module 6 so as to produce a 14-membered macrolide.
  • the extended PKS gene assemblies do produce macrolides with extended rings, i.e. in the case of erythomycin, a measurable quantity of 16-membered ring macrolide is produced.
  • extended PKS assemblies can be used to prepare larger than natural macrolides.
  • new rokitamycin (or leucomycin A5) analogues can conveniently be made from modified erythromycin gene assemblies.
  • Suitable plasmid vectors and genetically engineered cells suitable for expression of extended PKS genes are those described in PCT/GB97/01819 as being suitable for expression of hybrid PKS I genes.
  • effective hosts are Saccharopolyspora erythraea, Streptomyces coelicolor, Streptomyces avermitilis, Streptomyces griseofuscus, Streptomyces cinnamonensis, Micromonospora griseorubida, Streptomyces hygroscopicus, Streptomyces fradiae, Streptomyces longisporoflavus, Streptomyces lasaliensis, Streptomyces tsukubaensis, Streptomyces griseus, Streptomyces venezuelae, Streptomyces antibioticus, Streptomyces lividans, Streptomyces rimosus and Streptomyces albus. These include hosts in which SCP2 * -derived
  • S. griseofuscus and other hosts such as Saccharopolyspora erythraea in which SCP2*-derived plasmids become integrated into the chromosome through homologous recombination between sequences on the plasmid insert and on the chromosome; and all hosts which are integratively transformed by suicide plasmid vectors.
  • a plasmid containing "donor" PKS DNA is introduced into a host cell under conditions where the plasmid becomes integrated into an acceptor PKS gene assembly on the bacterial chromosome to create an extended PKS.
  • the donor PKS DNA includes a segment encoding an extension module.
  • Fig 2a is a diagram showing the functioning of 6-deoxyerythrondide synthase B (DEBS), a PKS producing 6-deoxyerythronolide B (6-
  • Fig 2b shows post-PKS biosynthesis of erythromycins including the conversion of 6-DEB to erythromycin A
  • Plasmid pCJR24 was prepared as described in PCT/GB97/01819. Restriction digestion, kinase end polishing and re-ligation techniques were used to remove the Sse8387l polylinker site from pCJR24 to give plasmid pCJR24-S.
  • An Sse8387l restriction site was created 6120 base pairs into the DEBSI-TE encoding gene using a polymerase chain reaction (PCR) strategy. The base changes which created this site did not introduce any amino acid mutations.
  • the DEBSI-TE encoding gene containing the Sse8387l site was introduced into pCJR24-S to give plasmid plB103.
  • Rapamycin module 2 was isolated as a Sse8387l fragment by restriction digestion. Changes to the DNA sequence to introduce sites was achieved using PCR and did not introduce any amino acid mutations. Rapamycin module 2 was taken from the amino acid sequence (ACR) at 9900 bases from the start of the rapA gene to the ACR at 14633 bases from the start of rapA.
  • ACR amino acid sequence
  • the resulting 4763 bp fragment of DNA containing the modified rapamycin module 2 was inserted as an Sse8387l fragment into Sse8387l-cut plB103 to yield pCJR54.
  • S. erythraea was tranformed with pCJR54 (transformation into S.erythraea is described in PCT/GB97/0 819) by homologous recombination. Selection of correct integrants was verified by selection of thiostrepton resistant clones. A single clone, no.6, was selected. S. erythraea NRRL2338/No. 5 was selected for its inability to glycosylate the erythromycin agtycone.
  • a frozen suspension of strain pCJR54/no.5/6 was used to inoculate 50ml of SV2 medium in a 250ml conical flask.
  • SV2 contained, per litre deionised water, glucose 15g, glycerol 15g, soy peptone 15g, NaCI 3g, CaCO 3 1g.
  • the pH was adjusted to 7.0 pre-autoclaving.
  • Thiostrepton was added pre-inoculation to give a concentration of 5 ⁇ g mL "1 .
  • This seed culture was shaken at 250rpm, 28°C, for 3 days and then used to inoculate the production medium SM3.
  • the production medium contained, per litre deionised water, glucose 5g, maltodextrin (glucidex) 50g, soya flour (arkasoy) 25g, beet molasses 3g, K 2 HPO 4 0.25g, CaCO 3 2.5g.
  • the pH was adjusted to 7.0 pre-autoclaving.
  • Thiostrepton was added to give a concentration of 5 ⁇ g mL "1 before inoculation.
  • the seed culture was used to inoculate (2% volume/volume) seven 2-litre florence flasks containing 300mL of SM3, which were shaken at 250rpm and 28°C for 7 days before harvest.
  • the fermentation broth (2L) was centrifuged at 4500rpm.
  • the cells and supernatant were separated by decantation and the pH of the supernatant was adjusted to pH9.5.
  • the resulting solution was extracted with ethylacetate (2L).
  • the ethylacetate layer was removed and evaporated under vacuum to yield 1.297g of oil.
  • a 500 MHz proton NMR spectrum of a solution in hexadeutero dimethyl sulphoxide at about 323°K includes peaks [ ⁇ values with muitipicities, coupling constants (Hz) and integration values in parentheses] centered at about:
  • a 500 MHz proton NMR spectrum of a solution in hexadeutero dimethyl sulphoxide includes peakes [ ⁇ values with muitipicities, coupling constants (Hz) and integration values in parentheses] centred at about:
  • a 500MHz proton NMR spectrum of a solution in hexadeutero dimethyl sulphoxide includes peaks [ ⁇ values with muitipicities, coupling constants (Hz) and integration values in parentheses] centred at about:
  • Plasmid plB126 was constructed as follows:
  • a Nhe ⁇ restriction site was created at 6063 bp into the DEBS1-TE gene using a polymerase chain reaction (PCR) strategy.
  • PCR polymerase chain reaction
  • the DEBS1-TE gene containing the ⁇ /hel site was cloned into pCJR24 to give plB117.
  • the rapamycin polyketide synthase module 5 was inserted into the Nhe ⁇ site in the linker region between ACP1 and KS2 from the DEBS1-TE gene. Changes to introduce a Nhe ⁇ site at either end of the rapamycin module 5 were introduced by PCR. This resulted in amino acid changes from AN to LA at the beginning and RT to LA at the end of the module, respectively.
  • the rapamycin module 5 was taken from position 67 bp (AN) to position 4873 bp (RT) from the start of rapB.
  • the resulting 4854 bp fragment, containing module 5 with Nhe ⁇ restriction sites at either end was inserted into plB117 at the Nhe ⁇ site to yield plasmid plB126.
  • S. erythraea was transformed with plB126. Integration of the plasmid into the chromosome was verified by selection of thiostrepton resistant clones. A single clone was selected.
  • a frozen suspension of S. erythraea NRLL2338/plB126 was inoculated into TSB medium containing thiostrepton (5 ug/ml). This seed culture was shaken at 250 rpm, 28°C, for 3 days and then used to inoculate the production medium SM3. The remaining fermentation steps were as described hereinbefore for Example 3.
  • Buffer A 10 mM Ammonium acetate + 0.1% formic acid
  • Buffer B 90% Acetonitrile/10% water; 10 mM ammonium acetate + 0.07% formic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne un groupe de gènes polycétide-synthase allongés, qui comprend un module de charge et une pluralité de modules d'élongation dans lesquels une deuxième partie d'acide nucléique, codant au moins un module d'élongation, a été insérée dans une première partie d'acide nucléique codant le module de charge et au moins un, ou de préférence plusieurs, module d'élongation. Lesdits gènes allongés conviennent pour la production de nouveaux macrolides présentant une taille plus grande que celle du produit naturel, par exemple des macrolides présentant un cycle à 16 chaînons au lieu de macrolides présentant un cycle à 14 chaînons.
EP99901036A 1998-01-14 1999-01-14 Polycetides et leur synthese Withdrawn EP1045912A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9800675.2A GB9800675D0 (en) 1998-01-14 1998-01-14 Polyketides and their synthesis
GB9800675 1998-01-14
GBGB9800879.0A GB9800879D0 (en) 1998-01-15 1998-01-15 Polyketides and their synthesis
GB9800879 1998-01-15
PCT/GB1999/000117 WO1999036546A1 (fr) 1998-01-14 1999-01-14 Polycetides et leur synthese

Publications (1)

Publication Number Publication Date
EP1045912A1 true EP1045912A1 (fr) 2000-10-25

Family

ID=26312934

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99901036A Withdrawn EP1045912A1 (fr) 1998-01-14 1999-01-14 Polycetides et leur synthese

Country Status (6)

Country Link
EP (1) EP1045912A1 (fr)
JP (1) JP2002508968A (fr)
AU (1) AU2066799A (fr)
CA (1) CA2318365A1 (fr)
HR (1) HRP20000474A2 (fr)
WO (1) WO1999036546A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358712B1 (en) 1999-01-05 2002-03-19 Trustee Of Boston University Ordered gene assembly
GB0327720D0 (en) 2003-11-28 2003-12-31 Biotica Tech Ltd Erythromycins and process for their preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013663A1 (fr) * 1992-01-17 1993-07-22 Abbott Laboratories Procede permettant d'effectuer la biosynthese de polycetides specifiques
JP3063943B2 (ja) * 1992-02-26 2000-07-12 明治製菓株式会社 血漿中において抗菌活性の持続する新規１６員環マクロリド誘導体及びその合成中間体とそれらの製造法
NZ333861A (en) * 1996-07-05 2000-08-25 Pfizer Erythromycins and preparation from unnatural starter units in microorganisms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9936546A1 *

Also Published As

Publication number Publication date
CA2318365A1 (fr) 1999-07-22
AU2066799A (en) 1999-08-02
JP2002508968A (ja) 2002-03-26
WO1999036546A1 (fr) 1999-07-22
HRP20000474A2 (en) 2000-12-31

Similar Documents

Publication Publication Date Title
JP4489947B2 (ja) ポリケチドとその合成
EP0910633B1 (fr) Gène de polyketide synthèse I hybride
CA2322449C (fr) Genes biosynthetiques de production d'insecticides a base de spinosyne
JP2003512013A (ja) 組換えオレアンドライドポリケチドシンターゼ
EP1045912A1 (fr) Polycetides et leur synthese
US7807418B2 (en) Method for producing hybrid polyketide synthases
WO2001068867A1 (fr) Polycetides et leur synthese
AU2008201937B2 (en) Biosynthetic genes for butenyl-spinosyn insecticide production
JP2009213479A (ja) ポリケチド類及びそれらの合成

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000712

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040309

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040720